Oral: Preclinical and Translational modelling to support drug discovery and development

Home / Oral: Preclinical and Translational modelling to support drug discovery and development

Oral: Preclinical and Translational modelling to support drug discovery and development

Time matters: Predicting gemcitabine exposure in the pediatric brain with diffuse midline glioma using LeiCNS-PK3.0

Thursday 7 May, 2026

Objectives: Gemcitabine shows strong in vitro promise against H3K27M-altered diffuse midline gliomas (DMGs), a rare and aggressive pediatric brain cancer…

Read more

A FAIR combination: guiding development of a novel immunomodulatory-antibiotic combination therapy using an integrative PKPD framework based on multi-source preclinical data

Thursday 7 May, 2026

Introduction: According to recent WHO reports, 17% of bacterial infections worldwide in 2023 were caused by pathogens with antimicrobial resistance…

Read more

Clip: a Translational PK/PD Tool to Predict ORR in Solid Tumors using PDX Data

Thursday 7 May, 2026

Introduction: Patient-derived xenograft (PDX) mouse models represent a key preclinical platform for evaluating anticancer drug efficacy, with large-scale PDX encyclopedias…

Read more

From mother to newborn: pregnancy PBPK-PD modeling for rozanolixizumab

Thursday 7 May, 2026

Objectives: For women living with chronic autoimmune diseases, adequate disease control during pregnancy is key to ensure the best maternal…

Read more